- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06188910
Neurofeedback and Nomophobia in Young Adults
Effectiveness of a Neurofeedback Intervention on Symptoms of Anxiety and Psychological Distress Associated With Smartphone Use in Young Adults
Introduction: Given the growing increase in addiction to social networks and smartphone use in young people and its implications for health, it is necessary to investigate effective interventions for the appropriate use of these technologies and coping with possible signs of addiction.
Objective: To evaluate the effect of an intervention based on neurofeedback techniques on anxiety and other disorders associated with problematic use of mobile phones and the internet in young adults.
Methodology: Randomised controlled clinical trial with two parallel groups: an intervention group (IG) and a control group (CG). The study population will be young adults aged 18-30 years. A sample size of 36 participants has been estimated, 18 in each group to detect a difference of 3.9 points or more on the DASS-21 anxiety questionnaire.
All participants will receive an educational workshop on the responsible use of new technologies and the promotion of healthy lifestyles. The IG, in addition to this educational workshop, will receive 20 neurofeedback sessions during 8 weeks, 2-3 sessions/week with the MUSE neurofeedback device.
A baseline and 3-month post-intervention assessment will be conducted for both groups to study change variables related to smartphone addiction (Smartphone Addiction Scale-Short Version (SAS-SV)), nomophobia (Nomophobia Questionnaire (NMP-Q)), depression, anxiety and stress (Depression, Anxiety and Stress Scale 21-item (DASS-21)) and sleep quality.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: José Ignacio Recio Rodriguez, PhD
- Phone Number: 650330694
- Email: donrecio@usal.es
Study Locations
-
-
-
Salamanca, Spain, 37005
- José Ignacio Recio Rodriguez
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have one or more mobile devices such as smartphones.
- Have a compatible mobile device to install and use the Muse: EEG Meditation & Sleep application.
- Be fully functional.
- Willingness to voluntarily participate in the study and sign the informed consent form.
Exclusion Criteria:
- History of severe psychiatric disorders (such as schizoaffective disorders, bipolar disorder, major depressive episode with symptoms or other non-organic psychotic disorders) requiring psychiatric treatment in the 6 months prior to study entry.
- History of brain injury or other problems contraindicating the use of neurofeedback.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neurofeedback
3 weekly 30-minute neurofeedback sessions per week for 12 weeks
|
Conducting neurofeedback sessions guided by a researcher
Other Names:
|
Active Comparator: Control
Health education, a 25-minute session, on mobile phone addiction and promotion of healthy lifestyles
|
Health education on mobile phone addiction
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anxiety
Time Frame: Baseline, 3-months
|
Anxiety evaluated through Depression, Anxiety and Stress Scale 21-item (DASS-21).
Minimum 0 - maximum 63
|
Baseline, 3-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nomophobia
Time Frame: Baseline, 3-months
|
Nomophobia evaluated through Nomophobia Questionnaire (NMP-Q).
Minimum 20 - maximum 140
|
Baseline, 3-months
|
Sleep Quality
Time Frame: Baseline, 3-months
|
Sleep quality evaluated through Atenas questionnaire.
Minimum 0 - maximum 24
|
Baseline, 3-months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: José Ignacio Recio Rodriguez, PhD, University of Salamanca
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IBYE23_00001 - GRS2709/A1/2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
Clinical Trials on Neurofeedback
-
Kowloon Hospital, Hong KongChinese University of Hong KongCompletedStroke | Cognitive ImpairmentHong Kong
-
Insel Gruppe AG, University Hospital BernUniversity of BernRecruiting
-
University of Rhode IslandRecruitingNeurofeedbackUnited States
-
University of OxfordWellcome TrustTerminated
-
Leiden University Medical CenterCompletedElevated EEG Theta/Beta Ratio
-
National Cheng-Kung University HospitalMinistry of Science and Technology, TaiwanEnrolling by invitationHIV Infections | Poor Quality SleepTaiwan
-
University of PittsburghRecruiting
-
Laureate Institute for Brain Research, Inc.CompletedDepression | AnxietyUnited States
-
Laureate Institute for Brain Research, Inc.National Institute of General Medical Sciences (NIGMS)RecruitingDepressive Disorder, MajorUnited States
-
ETH ZurichSwiss Epilepsy Centre - Klinik LenggRecruitingHealth, Subjective | Epilepsy, Temporal Lobe | Psychogenic SeizureSwitzerland